^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Thymoma

    Related cancers:
    1d
    Zingerone Inhibits ox-LDL-Induced Human Coronary Artery Endothelial Cells Senescence and Apoptosis in Association With Downregulation of HSP90AB1 in Coronary Artery Atherosclerotic Heart Disease. (PubMed, J Biochem Mol Toxicol)
    Zin suppresses inflammation, senescence, and apoptosis of oxidized low-density lipoprotein-induced primary human coronary artery endothelial cells in a manner associated with HSP90AB1 silencing. These findings provide a foundation for the further development of Zin-based treatment strategies for CHD.
    Journal • IO biomarker
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • AKT2 (V-akt murine thymoma viral oncogene homolog 2) • TLR4 (Toll Like Receptor 4) • HSP90AB1 (Heat Shock Protein 90 Alpha Family Class B Member 1)
    3d
    Integrated Molecular and Clinical Analysis of Thymic Epithelial Tumors. (PubMed, JCO Precis Oncol)
    Integrated profiling of TETs reveals distinct genomic, transcriptomic, and immune features across subtypes of TETs and identifies potentially actionable therapeutic targets that may inform future treatment strategies.
    Journal • Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • MTAP (Methylthioadenosine Phosphorylase) • MSLN (Mesothelin) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    PD-L1 expression • TP53 mutation • TMB-H • MSI-H/dMMR • PD-L1 overexpression • HER-2 overexpression • EGFR expression • TMB-L • CDKN2A deletion
    |
    MI Tumor Seek™
    8d
    Case Report: Anti-LGI1 encephalitis during FcRn inhibition with efgartigimod for myasthenia gravis: implications for the limitations of IgG recycling blockade. (PubMed, Front Immunol)
    High-dose intravenous methylprednisolone therapy resulted in marked clinical improvement. The absence of intrathecal IgG synthesis raises the possibility that pathogenic antibodies were predominantly derived from the peripheral compartment. These findings underscore the pharmacodynamic limitations of FcRn inhibition, particularly in the setting of thymoma-associated immune dysregulation.
    Journal
    |
    TTN (Titin)
    |
    methylprednisolone sodium succinate
    12d
    Reevaluating the nature of thymic lipofibroadenoma: A case report with hamartomatous features and a literature review. (PubMed, Medicine (Baltimore))
    This unique thymic lesion, featuring LFA-like areas admixed with duct-forming lobulated epithelial proliferation, is best classified as a thymic hamartoma. Review of the literature suggests that previously reported LFAs may also represent hamartomatous lesions rather than true neoplasms. Complete surgical resection appears curative. Further case accumulation and molecular studies are needed to elucidate the pathogenesis.
    Review • Journal
    |
    TP63 (Tumor protein 63)
    13d
    Pediatric mediastinal tumor unveiled as T-cell prolymphocytic leukemia: diagnostic pitfalls-a case report. (PubMed, J Med Case Rep)
    This case illustrates the diagnostic challenges of pediatric T-PLL and demonstrates that a multidisciplinary correlation of clinical, histological, immunophenotypic, and molecular features-together with repeated biopsy and comprehensive immunophenotyping-can be decisive for timely and accurate diagnosis.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD8 (cluster of differentiation 8) • CD33 (CD33 Molecule) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD5 (CD5 Molecule) • TP63 (Tumor protein 63)
    16d
    Comparative Study of Sporadic and Immune Checkpoint Inhibitor-Related Forms of Myasthenia Gravis-Myositis Overlap Syndrome. (PubMed, Neurology)
    Although they share some similarities, s-MG-IM represents a chronic, predominantly thymoma-associated overlap syndrome with classical MG and IM features, whereas ir-MG-IM is typically an aggressive, likely monophasic condition characterized by severe myositis, with frequent ocular and cardiac involvement, and lacking classical MG features. Study limitations include the retrospective design, small sample size, and limited serum availability, warranting confirmation in larger prospective cohorts.
    Clinical • Retrospective data • Journal • Checkpoint inhibition
    |
    TTN (Titin)
    20d
    Clinicogenomic Landscape of MTAP-Deleted Thoracic Malignancies Across US and Japanese Nationwide Cohorts: Impact of Concurrent CDKN2A Alterations and Driver Mutations. (PubMed, JCO Precis Oncol)
    MTAP-deleted thoracic tumors exhibit reproducible clinical and molecular features across populations. Our findings support the rational, globally applicable development of MTAP-targeted synthetic lethal strategies in thoracic malignancies, particularly in combination with molecular targeted agents.
    Journal • Tumor mutational burden • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • MTAP (Methylthioadenosine Phosphorylase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
    |
    EGFR mutation • ALK fusion • CDKN2A deletion • MTAP deletion • RB1 mutation
    22d
    SELECT-NK-THYM: Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma (clinicaltrials.gov)
    P1/2, N=36, Recruiting, Beijing Biotech
    New P1/2 trial
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • MSLN (Mesothelin) • CD5 (CD5 Molecule)
    |
    cyclophosphamide • fludarabine IV • rimiducid (AP1903)
    24d
    Case Report: Thymoma-associated stiff person syndrome and myasthenia gravis: an index case with exploratory exome sequencing and review of reported cases. (PubMed, Front Oncol)
    Thymoma-associated SPS and MG constitute a rare but recognizable overlap syndrome. Integration of clinical, literature and exploratory genomic data supports a convergent mechanism involving thymic epithelial neoplasia, impaired inhibitory neurotransmission and neuromuscular junction autoimmunity.
    Journal • IO biomarker
    |
    CACNA1A (Calcium Voltage-Gated Channel Subunit Alpha1 A)
    25d
    Anti-pituitary-specific transcription factor-1 hypophysitis developing after thymoma resection: a case report with review of literature. (PubMed, Endocr J)
    Replacement therapy with levothyroxine and recombinant human GH was initiated...This case highlights anti-PIT-1 hypophysitis as a potential post-thymectomy autoimmune complication and that central hypothyroidism should be considered in patients presenting with nonspecific symptoms after thymectomy. Further research is needed to delineate risk factors for susceptibility and to develop preventive strategies.
    Journal
    |
    IGF1 (Insulin-like growth factor 1)
    27d
    Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) (clinicaltrials.gov)
    P2, N=55, Active, not recruiting, European Organisation for Research and Treatment of Cancer - EORTC | Trial completion date: Jul 2024 --> Dec 2027
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab)
    1m
    Significant decreased CXCR3+ phenotype Tfh1 cells in three Good's syndrome patients. (PubMed, Front Immunol)
    Tfh17 cell percentages and Th1/Th2/Th17 cytokine profiles showed no significant alterations. Our findings reveal, for the first time, a pronounced decrease in circulating CXCR3+ Tfh1 cells in GS patients, suggesting a potential role for this specific immune imbalance in the disease's immunopathogenesis.
    Journal
    |
    CD4 (CD4 Molecule) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • CCR6 (C-C Motif Chemokine Receptor 6)